---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-025446"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:20:39.841730+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BullFrog AI announces USPTO issuance of patent for novel mebendazole prodrugs for cancer treatment

## Summary
- USPTO to issue Patent No. 11,712,435 on Aug 1, 2023, protecting novel prodrugs of mebendazole with improved solubility and oral bioavailability.
- This is the first patent from IP licensed from Johns Hopkins University in Oct 2022; BullFrog AI holds exclusive worldwide royalty-bearing rights.
- CEO Vin Singh says prodrugs address key difficulty in evaluating mebendazole for oncology, enhancing potential for glioblastoma and other cancers.
- Company intends to work with strategic partners to monetize the asset for clinical development.

## SEC filing metadata
- accession: 0001493152-23-025446
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315223025446/0001493152-23-025446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315223025446/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-025446
- JSON: https://secwatch.observer/filing/0001493152-23-025446.json
- Plain text: https://secwatch.observer/filing/0001493152-23-025446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.